1,000 Cases Completed with First Predictive Ligament Balancing Robot
| RAYNHAM, Mass., Oct. 3, 2018 /PRNewswire/ -- OMNIlife science, Inc. (“OMNI”), a privately-held, medical technology company targeting the $15 billion global hip and knee replacement device market, reported today that the positive clinical benefits of the OMNIBotics® Robotic Active Spacer continue to be reinforced by more than 1,000 successful procedures performed to date. Orthopaedic surgeons have been evaluating this revolutionary system that utilizes a miniature robot to ensure the ligaments will be “balanced” after the knee replacement.
A basic tenet of knee replacement is to balance the tension of the ligaments to ensure smoother knee function and better alignment. However, balancing frequently involves making small incisions in tighter ligaments to create equal ligament tension. The Active Spacer helps the surgeon position implants in anatomic alignment while maintaining ligament balance without having to incise ligaments. Early data on the use of the Active Spacer is showing a much higher rate of patient satisfaction at both three and six months’ post-surgery than what has been typically reported in the literature. “We are pleased the benefits of OMNIBotics Active Spacer technology continue to be validated by multiple surgeons,” said Rick Epstein, CEO of OMNI. “Our OMNIBotics robotic-assisted technology guides the surgeon to the optimal implant position to achieve both mechanical alignment and balance, and each of the cuts are made with robotic precision. We believe a properly aligned and carefully balanced knee will result in optimized patient outcomes and it is exciting to be working with surgeons to advance the field of knee replacement with robotics.” OMNIBotics with Active Spacer is the first and only robotic system to integrate ligament tension with bone alignment. “I’ve been doing knee surgery for 25 years,” stated Jeffrey H. DeClaire, M.D. (DeClaire LaMacchia Orthopedic Institute, Rochester Hills, MI), “and I’ve always been very focused on balancing the knee, but there’s never been any way to measure and validate ligament balance and ligament tension in knee arthroplasty until the OMNIBotics Active Spacer. This is a real breakthrough because now I know that each total knee arthroplasty I perform is precisely balanced with consistency and reproducibility that significantly improves the accuracy of the procedure, in addition to facilitating improved patient outcomes and patient satisfaction.” ABOUT OMNI OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com. FORWARD LOOKING STATEMENTS Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release. CONTACT Cindy Holloway, Director of Marketing Communications Phone: (508) 824-2444
SOURCE OMNIlife science, Inc. |
View original content to download multimedia:
